Document Detail

Volume-weighted mean nuclear volume and numerical nuclear density in the cardiomyocyte following enalapril and verapamil treatment.
MedLine Citation:
PMID:  11213841     Owner:  NLM     Status:  MEDLINE    
The estimation of the volume-weighted mean nuclear volume, nu(nu), and the numerical nuclear density in the plane, N(A), was used to analyze cardiomyocyte nuclei in the condition of cardiac hypertrophy caused by nitric oxide (NO) synthesis blockade and simultaneous antihypertensive treatment for 40 days (four groups of ten rats each: control, L-NAME, L-NAME+enalapril, L-NAME+verapamil). The blood pressure (BP) increased 71% in the L-NAME group. In the L-NAME+enalapril and L-NAME+verapamil groups, the BP did not show any alteration when compared with the respective controls. In comparison with the control group, nu(nu) was 250% greater, and the N(A) was 25% smaller in the L-NAME animals, while no difference occurred in the other two groups. With respect to cardiomyocyte nuclear size, the present results suggest a beneficial effect of the angiotensin-converting enzyme inhibitor enalapril and the calcium channel blocker verapamil when NO synthesis is blockaded.
C A Mandarim-de-Lacerda; L M Pereira
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Virchows Archiv : an international journal of pathology     Volume:  438     ISSN:  0945-6317     ISO Abbreviation:  Virchows Arch.     Publication Date:  2001 Jan 
Date Detail:
Created Date:  2001-02-13     Completed Date:  2001-03-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9423843     Medline TA:  Virchows Arch     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  92-5     Citation Subset:  IM    
Laboratory of Morphometry and Cardiovascular Morphology, Centro Biomédico, Instituto de Biologia, State University of Rio de Janeiro, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin-Converting Enzyme Inhibitors / pharmacology
Antihypertensive Agents / pharmacology*
Calcium Channel Blockers / pharmacology
Cell Nucleus / drug effects*,  ultrastructure*
Enalapril / pharmacology*
Enzyme Inhibitors / pharmacology
Myocardium / ultrastructure*
NG-Nitroarginine Methyl Ester / pharmacology
Nitric Oxide Synthase / antagonists & inhibitors
Rats, Wistar
Verapamil / pharmacology*
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Calcium Channel Blockers; 0/Enzyme Inhibitors; 50903-99-6/NG-Nitroarginine Methyl Ester; 52-53-9/Verapamil; 75847-73-3/Enalapril; EC Oxide Synthase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Immunohistochemical analysis of the proliferative activity of neuroendocrine tumors from various org...
Next Document:  Personality disorders in the community: a report from the Australian National Survey of Mental Healt...